David Veitch, Basilea CEO (Vimeo via Basilea website)

In an un­usu­al piv­ot, Swiss biotech Basilea looks to ditch can­cer pipeline in fa­vor of — an­ti-in­fec­tives?

On­col­o­gy has been the sin­gle largest dri­ver of rev­enues across bio­phar­ma for years now, and you’re more like­ly than ever to see a com­pa­ny ditch all oth­er plans to chase that white rab­bit. But a Swiss biotech is bet­ting its fu­ture on a per­pen­dic­u­lar path, opt­ing to ditch its on­col­o­gy as­sets in­stead.

Switzer­land-based Basilea will look to of­fload its on­col­o­gy pipeline in part or in full as part of a re­or­ga­ni­za­tion of its R&D pipeline around an­ti-in­fec­tives, in­clud­ing its two ap­proved drugs in that space, the biotech said Tues­day.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.